MD Anderson and UroGen Pharma Announce Strategic Research Collaboration to Advance Investigational Treatment for High-grade Bladder Cancer
January 14, 2021
January 14, 2021
HOUSTON, Texas, Jan. 14 -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 13:
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
UroGen's approach involves the loca . . .
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for the treatment of high-grade non-muscle invasive bladder cancer (HG-NMIBC).
UroGen's approach involves the loca . . .